Marinus Pharms

MRNS NASDAQ
3.980
+0.090
+2.31%
After Hours: 3.980 0 0.00% 16:25 07/22 EDT
Open
3.990
Prev Close
3.890
High
4.100
Low
3.860
Volume
434.20K
Avg Vol (3M)
503.81K
52 Week High
10.54
52 Week Low
2.360
% Turnover
0.83%
Market Cap
209.17M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Marinus Pharms MRNS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
MORE >

Recently

Name
Price
%Change